- Reference #:
- FEI 3005241015
Recipient NameWoo Sung Kee
Recipient TitleVice-Chairman / CEO
- Celltrion Inc.
- Issuing Office:
- Center for Drug Evaluation and Research
Dear Mr. Kee,
The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 320-18-28 issued on January 26, 2018. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Lixin (Leo) Xu, M.D., Ph.D.
Global Compliance Branch 2 (GCB2)
Division of Drug Quality I (DDQI)
Office of Manufacturing Quality (OMQ)
Office of Compliance (OC)
Center for Drug Evaluation and Research (CDER)